Pax2 Expression Is Correlated With Better Survival in Tamoxifen-Treated Breast Carcinoma Patients

Pax2 Expression Is Correlated With Better Survival in Tamoxifen-Treated Breast Carcinoma Patients Publisher Pubmed

Jahangiri R¹ ; Mosaffa F^{2, 3} ; Gharib M⁴ ; Emami Razavi AN⁵ ; Abdirad A⁶ ; Jamialahmadi K^{1, 2}

Show Affiliations

1. Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
3. Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
4. Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5. Iran National Tumor Bank, Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran
6. Department of Pathology, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran

Source: Tissue and Cell Published:2018

Abstract

PAX2 (paired box gene 2) is a transcription factor, which is involved in both cell proliferation and carcinogenesis. This study aimed to investigate PAX2 expression in tamoxifen resistant (TAM-R) and tamoxifen sensitive (TAM-S) breast carcinoma patients and analyze its correlation with clinicopathological characteristics and survival. Immunohistochemical analysis was performed to evaluate PAX2 protein expression in 36 TAM-R and 36 TAM-S formalin-fixed paraffin-embedded (FFPE) breast tumor tissues. Data analysis indicated that PAX2 expression was significantly higher in TAM-S group in comparison to TAM-R (P = 0.014). Overexpression of PAX2 was significantly correlated with perineural invasion (PNI) (P = 0.025). Kaplan–Meier survival analysis showed significant association between high expression of PAX2 and better disease-free survival (P < 0.001) and also overall survival (P = 0.031). Multivariate cox regression analysis demonstrated that patients with increased expression of PAX2 have a trend toward improved disease free survival (OR = 0.065, 95% CI: 0.009–0.476; P = 0.007) and overall survival (OR = 0.147, 95% CI: 0.020-1.105; P = 0.062). Our data suggested that high expression of PAX2 could be associated with better survival in estrogen receptor positive tamoxifen-treated breast carcinoma patients. © 2018 Elsevier Ltd

Related Docs

View other Related Docs

1. Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance Is Required, Current Cancer Drug Targets (2018)

2. Challenges of Endocrine Therapy in Breast Cancer, Cancer Genetics and Psychotherapy (2017)

3. Increased Expression of Gankyrin and Stemness Factor Oct-4 Are Associated With Unfavorable Clinical Outcomes and Poor Benefit of Tamoxifen in Breast Carcinoma Patients, Pathology and Oncology Research (2020)

4. Expression and Clinicopathological Significance of Dna Methyltransferase 1, 3A and 3B in Tamoxifen-Treated Breast Cancer Patients, Gene (2019)

5. Muc1 Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer, Expert Review of Anticancer Therapy (2017)

6. Significant Role of Muc1 in Development of Resistance to Currently Existing Anti-Cancer Therapeutic Agents, Current Cancer Drug Targets (2018)

7. Gdnf Induces Ret–Src–Her2-Dependent Growth in Trastuzumab-Sensitive But Src-Independent Growth in Resistant Breast Tumor Cells, Breast Cancer Research and Treatment (2017)

8. Anti–Muc1 Nanobody Can Synergize the Tamoxifen and Herceptin Effects on Breast Cancer Cells by Inducing Er, Pr and Her2 Overexpression, International Immunopharmacology (2023)

Experts (# of related papers)

Elham Mirzaean (1)

Salma Sefidbakht (1)

Style	Citing Format
MLA	Jahangiri R, et al.. "Pax2 Expression Is Correlated With Better Survival in Tamoxifen-Treated Breast Carcinoma Patients." Tissue and Cell, vol. 52, no. , 2018, pp. 135-142.
APA	Jahangiri R, Mosaffa F, Gharib M, Emami Razavi AN, Abdirad A, Jamialahmadi K (2018). Pax2 Expression Is Correlated With Better Survival in Tamoxifen-Treated Breast Carcinoma Patients. Tissue and Cell, 52(), 135-142.
Chicago	Jahangiri R, Mosaffa F, Gharib M, Emami Razavi AN, Abdirad A, Jamialahmadi K. "Pax2 Expression Is Correlated With Better Survival in Tamoxifen-Treated Breast Carcinoma Patients." Tissue and Cell 52, no. (2018): 135-142.
Harvard	Jahangiri R et al. (2018) 'Pax2 Expression Is Correlated With Better Survival in Tamoxifen-Treated Breast Carcinoma Patients', Tissue and Cell, 52(), pp. 135-142.
Vancouver	Jahangiri R, Mosaffa F, Gharib M, Emami Razavi AN, Abdirad A, Jamialahmadi K. Pax2 Expression Is Correlated With Better Survival in Tamoxifen-Treated Breast Carcinoma Patients. Tissue and Cell. 2018;52():135-142.
BibTex	@article{ author = {Jahangiri R and Mosaffa F and Gharib M and Emami Razavi AN and Abdirad A and Jamialahmadi K}, title = {Pax2 Expression Is Correlated With Better Survival in Tamoxifen-Treated Breast Carcinoma Patients}, journal = {Tissue and Cell}, volume = {52}, number = {}, pages = {135-142}, year = {2018} }
RIS	TY - JOUR AU - Jahangiri R AU - Mosaffa F AU - Gharib M AU - Emami Razavi AN AU - Abdirad A AU - Jamialahmadi K TI - Pax2 Expression Is Correlated With Better Survival in Tamoxifen-Treated Breast Carcinoma Patients JO - Tissue and Cell VL - 52 IS - SP - 135 EP - 142 PY - 2018 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract